Posts tagged Alcobra
Alcobra and Arcturus agree to merge

Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively.

Read More
Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult patients with ADHD, known as the “MEASURE” study.

Shares of Alcobra were quoted at $2.55 at midday Friday.

Read More